Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.
The ruthenium-dimethylsulfoxide complex Na(trans-RuCl4(DMSO)Im] was given i.v. to mice bearing MCa mammary carcinoma and its effects on tumor growth and on healthy host tissues were studied by macroscopic examination of primary tumor growth, by survival time, and by histological analysis using light microscopy and SEM. Either by means of vivo-vivo bioassays or by microscopic examination it appeared that the growth of lung tumors was markedly reduced, whereas the growth of the i.m. primary tumor was much less affected. These effects account for the prolongation of survival time and for the cure rate observed. The favourable effect on survival time was also influenced by the lack of significant cytotoxicity for normal tissues such as lung and kidney epithelia, muscle and liver cells, splenocytes and bone marrow. It thus appears that the selective interaction with tumor cells in the lungs cannot simply be attributed to a selectively higher localization of the compound at this site, nor to a modification of the histological structure of primary tumor. These results highlight the pharmacologic properties of this compound for the control of solid tumor metastases, an effect that was shown to be similarly exerted on advanced tumor metastases.
Gagliardi
R
R
Fondazione C. e D. Callerio, Laboratories of Biological Research, Trieste, Italy.
Sava
G
G
Pacor
S
S
Mestroni
G
G
Alessio
E
E
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004121:Dimethyl Sulfoxide / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008168:Lung / Q000187:drug effects; D008175:Lung Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000556:secondary*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008808:Mice, Inbred CBA; D009942:Organometallic Compounds / Q000627:therapeutic use*; D017975:Ruthenium Compounds / Q000627:therapeutic use*
D004273:DNA, Neoplasm; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; C075498:dimethylsulfoxideimidazoletetrachlororuthenate(III); D004121:Dimethyl Sulfoxide